Purchase this article with an account.
Julien Gozlan, Agathe Cazet-Supervielle, Sahbi Rouissi, Chloe De Beketch, Michèle Boissonnot, Nicolas Leveziel; Intravitreal Ranibizumab in daily clinical practice for age-related macular degeneration.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3888.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe anatomical and functional outcomes of patients with exudative age-related macular degeneration undergoing Ranibizumab therapy with a pro renata strategy in the real-life practice.
Retrospective analysis of patients with wet age-related macular degeneration treated with a pro renata strategy. Visual acuity and OCT characteristics at baseline and at the end of the follow-up, clinical forms of the disease, delay between diagnosis and treatment, number of follow-up visits and number of intravitreal injections were collected for each patient.
One hundred and seventy nine patients (220 eyes) were followed during a mean of 24 months. The mean delay between diagnosis and treatment was 20.3 ± 16.8 days. The mean number of injections per year was 5.1 and the mean number of follow-up visits per year was 5. 20.5% of eyes gained ≥ 15 letters ETDRS, 31.8% lost ≥ 15 letters ETDRS and VA stabilization was observed in 44,1% of eyes. The central retinal thickness decreased of 295.6 ± 129.4 µm. In the multivariate analysis, lower baseline VA score was associated with greater gain of letters (OR=1.04; IC95% 1.02-1.06, p<0.001).
This study provides real-life data on patients suffering from exudative AMD and treated with Ranibizumab.
This PDF is available to Subscribers Only